Related references
Note: Only part of the references are listed.Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis.
V. Rimkunas et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease
Federica Borghese et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer
Marcello Tiseo et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Taming Glioblastoma by Targeting Angiogenesis: 3 Years Later
Eric T. Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models
E. Normant et al.
ONCOGENE (2011)
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Ting-Lei Gu et al.
PLOS ONE (2011)
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Chenguang Li et al.
PLOS ONE (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The biology and treatment of EML4-ALK non-small cell lung cancer
Takaaki Sasaki et al.
EUROPEAN JOURNAL OF CANCER (2010)
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors
Ibrahim M. El-Deeb et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2009)
FN3: a new protein scaffold reaches the clinic
Laird Bloom et al.
DRUG DISCOVERY TODAY (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
Ultan McDermott et al.
CANCER RESEARCH (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis
Huqun et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Anna V. Galkin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice
Al Charest et al.
CANCER RESEARCH (2006)
The sodium phosphate cotransporter family SLC34
H Murer et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2004)
The little R cell that could
R Nagaraj et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2004)
Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts
S Uttamsingh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
A Charest et al.
GENES CHROMOSOMES & CANCER (2003)
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma
A Charest et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The role of phosphatidylinositol 3-kinase, Rho family GTPases, and STAT3 in Ros-induced cell transformation
KT Nguyen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Association of a novel PDZ domain-containing peripheral golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6
A Charest et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Negative regulation of Ros receptor tyrosine kinase signaling:: An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1
H Keilhack et al.
JOURNAL OF CELL BIOLOGY (2001)
Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation
LY Zeng et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
The Sevenless signaling pathway: variations of a common theme
T Raabe
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2000)
Share Paper
